Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q3 2016 · 10-Q
Revenue$101.14K$101.14K−8.7% vs Q3 2015 Net Income-$213.99K-$213.99KN/M vs Q3 2015 EPS Diluted-$0.01-$0.01— vs Q3 2015 Gross Profit$62,940+46.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,937N/M Margins · derivedGross margin62.2%+23.4 pt vs Q3 2015
Operating margin-209.6%
Net margin-211.6%
ended Sep 30, 2016 · filed Dec 9, 2016 · 70 d after period end